Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use Alhemo safely and effectively. See full prescribing information for Alhemo.Alhemo® (concizumab-mtci) injection, for subcutaneous useInitial U.S. Approval: 2024
Medication labelWhy this: Advisory · dailymed-prescription
Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: •hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors •hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors
- generic_name
- concizumab
- product_names
- concizumab
- ndc
- 0169-2084, 0169-2084-15, 0169-2080, 0169-2080-15, 0169-2081, 0169-2081-03
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en